25 +
Basic Cell Lines
13 +
Resistant Pairs
10 +
Tumor Entities
4-6
Weeks Turnaround
Why OncoSelect™?
Precision oncology demands robust preclinical models. Our panel integrates well-characterized tumor cell lines, drug-resistant derivatives, and tumor microenvironment components to bridge the gap between in vitro pharmacology and clinical translation.
Genomically Defined
Each line is annotated with the principal driver mutations and target pathway, enabling mechanism-of-action–driven model selection rather than empirical screening.
EGFR · KRAS · BRAF · HER2 · BCR-ABL · FLT3 · PIK3CA · TP53
Data Support
All lines are qualified for 2D viability (survival / MTT / resazurin), 7-point dose-response IC50, 3D spheroid growth, and PBMC / NK co-culture assays.
CTG · IC₅₀ · 3D Spheroid · Co-culture
QC-Controlled
Identity confirmed by STR profiling, mycoplasma-negative by qPCR, and supplied with passage number, cell culture recommendations.
STR · Mycoplasma · CoA included
How to Choose? The Basic or Pro Panel?
Use Basic for early-stage hit triage, Pro for lead optimization and indication expansion, and Custom when your asset requires bespoke disease subtypes, resistance pairs, or isogenic backgrounds.
OncoSelect™ Basic — 25 Cell Lines
25 Well-Characterized Cell Lines, representing 10 major tumor entities with documented genomic profiles and clinical relevance, are recommended for chemotype triage and primary cytotoxicity ranking.
| Cell Model | Type | Indication | Key Features | Application |
| Cell Model | Type | Indication | Key Features | Application |
| A549 | NSCLC (adenocarcinoma) | KRAS G12S, TP53 wt | Baseline model for lung cancer and broad-spectrum anti-cancer drug screening | |
| PC-9 | NSCLC (adenocarcinoma) | EGFR ex19del | EGFR sensitizing mutation; highly sensitive to first/second-generation EGFR-targeted agents | |
| NCI-H1975 | NSCLC | EGFR L858R/T790M | Double EGFR mutation; model for acquired resistance to first/second-gen TKIs and osimertinib testing | |
| MCF-7 | Breast carcinoma | PIK3CA E545K, ER+ | First-line model for endocrine therapy and hormone-dependent drug screening | |
| MDA-MB-231 | Breast carcinoma (TNBC) | KRAS G13D, BRAF G464V, TP53 mut | Triple-negative; highly malignant and metastatic. Model for anti-metastatic and anti-invasion drug screening | |
| T-47D | Breast carcinoma | PIK3CA H1047R, ER+ | First-line model for endocrine therapy and hormone-dependent drug screening | |
| HCT116 | Colon carcinoma | KRAS G13D, PIK3CA H1047R, MSI-H | Rapid proliferation; sensitive to multiple cytotoxic agents; mismatch repair-deficient model | |
| HT-29 | Colon adenocarcinoma | BRAF V600E, TP53 mut | BRAF inhibitor screening; colorectal cancer resistance mechanism studies | |
| SW620 | Colon adenocarcinoma | KRAS G12V, TP53 R273H | Intestinal tumor drug screening and resistance mechanism research; lymph node metastasis derivative | |
| HepG2 | Hepatoblastoma | CTNNB1 mut, TP53 wt | Retains partial hepatic CYP enzyme function; dual use for efficacy and early hepatotoxicity assessment | |
| Huh7 | Hepatocellular carcinoma | TP53 Y220C | Frequently paired with HepG2 for comparative hepatotoxicity and efficacy evaluation | |
| MKN-45 | Gastric carcinoma | MET amplified | First-choice positive control for c-MET kinase inhibitors, ADCs, and bispecific antibodies. Highly invasive; metastasis model | |
| PANC-1 | Pancreatic ductal adenocarcinoma | KRAS G12D, TP53 R273H | Poorly differentiated, highly invasive. Prone to EMT; frequently co-cultured with CAFs in 3D | |
| BxPC-3 | Pancreatic ductal adenocarcinoma | KRAS wt, TP53, SMAD4, CDKN2A | Rare KRAS wild-type chassis; negative control for KRAS-targeted agents. High Trop-2 expression for ADC screening | |
| SK-OV-3 | Ovarian serous cystadenocarcinoma | HER2 amplified, PIK3CA H1047R | Ovarian cancer chemotherapy and targeted drug sensitivity testing | |
| A2780 | High-grade ovarian serous adenocarcinoma | TP53 wt, sensitive control | Ovarian cancer chemotherapy and targeted drug sensitivity testing | |
| OVCAR8 | High-grade ovarian serous adenocarcinoma | p53 del HER2 partial amp | Rapid proliferation; anti-apoptotic; naturally resistant to TNF and multiple cytotoxic drugs | |
| K562 | Chronic myeloid leukemia | BCR-ABL t(9;22) | Positive control for imatinib and other TKIs; MHC-I negative; standard NK cell activity target | |
| RAJI | Burkitt lymphoma | MYC t(8;14), EBV+ | Classic model for rituximab and B-cell-targeted agents (CAR-T, ADC) validation | |
| Jurkat | T-ALL | PTEN null, NOTCH1 mut | T-cell signaling model; can be engineered into reporter lines for immunomodulator screening | |
| A375 | Melanoma | BRAF V600E | Absolute gold standard for melanoma-targeted drug testing | |
| SK-MEL-28 | Melanoma | BRAF V600E | BRAF/MEK inhibitor sensitivity testing; acquired resistance modeling via long-term drug pressure | |
| U87-MG | Glioblastoma | PTEN null, CDKN2A loss | Most widely used GBM line; intracranial orthotopic models for oncolytic virus and targeted drug testing | |
| U-251 MG | Astrocytoma | p53 mut, PTEN mut | Radioresistant; used for radiosensitizer screening and combined chemoradiation evaluation | |
| 786-O | Renal cell carcinoma | VHL loss, HIF2α dependent | Benchmark model for multi-target TKIs (sunitinib, sorafenib) |
OncoSelect™ Pro — Parent/Resistant Pairs + Tumor Microenvironment
Expanded panel with drug-resistant derivatives, cancer-associated fibroblasts (CAFs), and tumor-associated endothelial cells (TECs). Designed for acquired resistance mechanism studies, combination therapy optimization, and stroma-dependent efficacy assessment.
| Cell Model | Type | Key Features | Application |
| Cell Model | Type | Key Features | Application |
| A549/taxol | Taxol-resistant derivative | Taxol-resistant derivative; taxane resistance in KRAS-mutant lung cancer context | |
| Lung Adeno CAFs | Stroma | Human Lung Adenocarcinoma Cancer Associated Fibroblasts — adenocarcinoma stromal modeling | |
| Lung SCC CAFs | Stroma | Human Lung Squamous Cell Carcinoma Cancer Associated Fibroblasts — SCC stromal interaction | |
| Lung Adeno TECs | Endothelial | Human Lung Tumor-Associated Endothelial Cells (Adenocarcinoma) — adenocarcinoma vascular targeting | |
| Lung SCC TECs | Endothelial | Human Lung Tumor-Associated Endothelial Cells (Squamous Cell) — SCC vascular targeting | |
| MCF-7/Palbociclib | Palbociclib-resistant derivative | Palbociclib-resistant derivative; CDK4/6 inhibitor resistance mechanism studies | |
| T47D/Palbociclib | Palbociclib-resistant derivative | Palbociclib-resistant derivative; cross-resistance profiling with MCF-7/Pal | |
| Breast CAFs | Stroma | Human Breast Cancer Associated Fibroblasts — stroma-dependent efficacy and anti-fibrotic drug testing | |
| Breast TECs | Endothelial | Human Breast Tumor-Associated Endothelial Cells — anti-angiogenesis and vascular targeting assessment | |
| HCT-15 | KRAS G13D, PIK3CA E545K;D549N, MSI-H | Colorectal carcinoma — baseline for drug sensitivity and resistance modeling | |
| LOVO | KRAS G13D, MSI-H | Colorectal carcinoma — baseline for drug sensitivity and resistance modeling | |
| HCT-15/Taxol | Taxol-resistant derivative | Taxol-resistant derivative; microtubule-targeting agent resistance mechanisms | |
| HCT-15/5FU | 5-Fluorouracil-resistant derivative | 5-Fluorouracil-resistant derivative; thymidylate synthase-mediated resistance | |
| LoVo/Onvansertib | Onvansertib-resistant derivative | Onvansertib-resistant derivative; PLK1 inhibitor resistance mechanisms | |
| SW620-Onvansertib | Onvansertib-resistant derivative | Onvansertib-resistant derivative; comparative resistance with LoVo/Onvansertib | |
| Colorectal CAFs | Stroma | Human Colorectal Cancer Associated Fibroblasts — stromal drug response and desmoplasia modeling | |
| Colon TECs | Endothelial | Human Colon Tumor-Associated Endothelial Cells — vascular targeting in colorectal cancer | |
| AsPc-1 | KRAS G12D, TP53, SMAD4 | Pancreatic carcinoma — baseline for drug sensitivity and resistance modeling | |
| ASPC-1/GEM | Gemcitabine-resistant derivative | Gemcitabine-resistant derivative; nucleoside analog resistance and combination strategies | |
| PANC-1/GEM | Gemcitabine-resistant derivative | Gemcitabine-resistant derivative; comparative resistance with ASPC-1/GEM | |
| Pancreatic CAFs | Stroma | Human Pancreatic Cancer Associated Fibroblasts — dense stromal microenvironment modeling | |
| OVCAR-8/ADR | Adriamycin-resistant derivative | Adriamycin-resistant derivative; anthracycline resistance and MDR pump studies | |
| A2780/cis | Cisplatin-resistant derivative | Cisplatin-resistant derivative; DNA damage response and platinum resistance mechanisms | |
| A2780/Taxol | Taxol-resistant derivative | Taxol-resistant derivative; microtubule stabilizer resistance; triple-resistant ovarian model | |
| Metastatic Ovarian CAFs | Stroma | Human Metastatic Ovarian Cancer Associated Fibroblasts — metastatic microenvironment modeling | |
| Ovarian CAFs | Stroma | Human Ovarian Cancer Associated Fibroblasts — primary tumor stromal interaction studies | |
| Ovarian TECs | Endothelial | Human Ovarian Tumor-Associated Endothelial Cells — peritoneal dissemination vascular targeting | |
| K562/Adr | Adriamycin-resistant derivative | Adriamycin-resistant derivative; ABC transporter-mediated multidrug resistance (MDR) studies |
Frequently Asked Questions
How are cell lines authenticated?
Every line undergoes STR profiling at the latest working stock generation. Mycoplasma screening is performed by qPCR before release.
Can I mix lines across tiers or request a subset?
Yes. Both Basic and Pro tiers are configurable — you can substitute lines or add custom models without recreating the full panel. Pricing is adjusted on a per-line basis.
What is the expected assay window and reproducibility?
For CTG-based viability assays, Z' factors are typically > 0.6 at the recommended seeding density. Inter-assay CV is generally < 15% for IC50 values across triplicate plates. Specific assay windows are provided in each line's data sheet.
Do you offer screening as a service (CRO mode)?
Yes. Customers can either receive the cells in-house or commission us to run CTG, IC50, 3D spheroid, or co-culture assays in our laboratories, with raw data, curve fits, and an interpretive report delivered. CRO engagement is available for all three tiers.
Ready to accelerate your oncology program?
Talk to our scientific team about the Tumor Efficacy Panel — Basic, Pro, or Custom — and receive a model-selection recommendation tailored to your asset and indication strategy.
